Editor's Favorite: "A Phase 1 Trial of Cabazitaxel Combined With 188Re–Hydroxyethylidene Diphosphonate in Patients With Metastatic Castration-Resistant Prostate Cancer Who Progressed on or After a Docetaxel-Containing Treatment : The ReCab Trial​" by JM van Dodewaard-de Jong.  Combined Cabazitaxel with 188Re was delivered to 12 patients with metastatic castration-resistant prostate cancer.  This was generally well tolerated with similar hematologic toxicity compared with cabazitaxel monotherapy.​

Current Issue


A Phase 1 Trial of Cabazitaxel Combined With 188Re–Hydroxyethylidene Diphosphonate in Patients With Metastatic Castration-Resistant Prostate Cancer Who Progressed on or After a...

van Dodewaard-de Jong, Joyce M.; Bouman-Wammes, Esther W.; Bloemendal, Haiko J.; More

Clinical Nuclear Medicine . 42(6):415-420, June 2017.

Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment

Hamiditabar, Mohammadali; Ali, Muzammil; Roys, Joseph; More

Clinical Nuclear Medicine . 42(6):436-443, June 2017.

Multiple Time-Point 68Ga-PSMA I&T PET/CT for Characterization of Primary Prostate Cancer: Value of Early Dynamic and Delayed Imaging

Schmuck, Sebastian; Mamach, Martin; Wilke, Florian; More

Clinical Nuclear Medicine . 42(6):e286-e293, June 2017.



1 2 3 4 5